Fig. 8
From: Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression
KDM5A promotes tumorigenicity by downregulating MOB3B expression in nude mice via the miR-495/YTHDF2 axis. a-c, Xenograft tumors and quantitative analysis of tumor size and volume after oe-KDM5A or oe-KDM5A + oe-MOB3B treatment. Scale bar = 10 mm in panel A. d, mRNA expression of KDM5A, YTHDF2 and MOB3B in mice following oe-KDM5A or oe-KDM5A + oe-MOB3B treatment detected by RT-qPCR. e, Western blots of KDM5A, YTHDF2 and MOB3B proteins in mice following oe-KDM5A or oe-KDM5A + oe-MOB3B treatment. f, miR-495 expression in mice following oe-KDM5A or oe-KDM5A + oe-MOB3B treatment detected by RT-qPCR. g, m6A modification level of MOB3B in mice following oe-KDM5A or oe-KDM5A + oe-MOB3B treatment assessed using Me-RIP. * p < 0.05 vs. cells transfected with oe-NC. # p < 0.05 or ns p > 0.05 vs. cells transfected with oe-KDM5A + oe-NC. Data in panel A and C-G were analyzed by one-way ANOVA with Tukey’s post hoc test, and those in panel B were analyzed by repeated measures ANOVA with Bonferroni’s post hoc test